Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes

American Journal of Managed Care

Volumn 9, Issue 9, 2003, Pages 606-615

  So, Wing Yee ^a   Tong, Peter C Y ^a   Ko, Gary T C ^a   Leung, Wilson Y S ^a   Chow, Chun Chung ^a   Yeung, Vincent T F ^a   Chan, Wing Bun ^a   Critchley, Julian A J H ^a   Cockram, Clive S ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FRUCTOSAMINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HOSPITAL; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MODEL; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE; OUTCOMES RESEARCH; OUTPATIENT CARE; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL RATE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG MONITORING; ENALAPRIL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HONG KONG; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; OUTPATIENT CLINICS, HOSPITAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0141921573     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-334.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
3. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-131.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405-412.
5. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321:412-419.
6. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
7. Florkowski CM, Scott RS, Moir CL, Graham PJ. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabet Med. 1998;15:386-392.
8. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354-1359.
9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
10. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
11. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
12. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care. 2002;25(suppl 1):S1-147.
13. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. BMJ. 1992;305:981-985.
14. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590-600.
15. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care. 1995;18:1013-1016.
16. Niskanen L, Turpeinen A, Penttila I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: A 15-year follow-up from the time of diagnosis. Diabetes Care. 1998;21:1861-1869.
17. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T. A 15-year follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan. Long-term prognosis and causes of death. Diabetes Res Clin Pract. 1996;34:47-55.
18. 1c. Am J Manag Care. 2000;6:1217-1226.
19. Norris SL, Nichols PJ, Caspersen CJ, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med. 2002;22:15-38.
20. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet. 1999;353:617-622.
21. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
22. MacDonald D, Pang CP, Cockram CS, Swaminathan R. Fructosamine measurements in serum and plasma. Clin Chim Acta. 1987;168:247-252.
23. Friedewald WT, Levy, RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
25. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
26. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
27. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610-630.
28. 1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999;22:1785-1789.
29. Saddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
30. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
31. Beckles GL, Engelgau MM, Venkat Narayan KM, Herman WH, Aubert RE, Williamson DF. Population-based assessment of the level of care among adults with diabetes in the US. Diabetes Care. 1998;21:1432-1438.
32. Larme AC, Pugh JA. Attitudes of primary care providers towards diabetes: Barriers to guideline implementation. Diabetes Care. 1998;21:1391-1396.
33. Bernard AM, Anderson L, Cook CB, Phillips L. What do internal medicine residents need to enhance their diabetes care? Diabetes Care. 1999;22:661-666.
34. Wetzler HP, Snyder JW. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care. 2000;23:1637-1641.
35. Simon LPS, Albright A, Belman MJ, Tom E, Rideout JA. Risk and protective factors associated with screening for complications of diabetes in a health maintenance organisation setting. Diabetes Care. 1999;22:208-221.
36. Ho M, Marger M, Beart J, Yip I, Shekelle P. Is the quality of diabetes care better in a diabetes clinic than in a general medicine clinic? Diabetes Care. 1997;20:472-475.
37. Mayfield JA, Rith-Najarian SJ, Acton KJ, et al. Assessment of diabetes care by medical record review. Diabetes Care. 1994;17:918-923.
38. Pommer W, Bressel F, Chen F, Molzahn M. There is room for improvement of preterminal care in diabetic patients with end stage renal failure - The epidemiological evidence in Germany. Nephrol Dial Transplant. 1997;12:1318-1320.
39. El-Kebbi IM, Ziemer DC, Musey VC, Gallina DL, Bernard AM, Phillips LS. Diabetes in urban African-Americans, IX: Provider adherence to management protocols. Diabetes Care. 1997;20:698-703.
40. Medication adherence may reduce mortality and morbidity [review]. ACP J Club. 1998;128:53.
41. Liniger C, Albeanu A, Bloise D, Assal JP. The tuning fork revisited. Diabet Med. 1990;7:859-864.
42. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: John Hopkins University Press; 1979:11-22.
43. Lee A, Chan JCN. Shared care in diabetes mellitus - Why is it important. Hong Kong Pract. 1997;19:315-322.
44. Lee A, Chan JCN. Shared care in diabetes mellitus - What are the obstacles. Hong Kong Pract. 1997;17:323-330.
45. Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;258:1687-1692.
46. Verlato G, Muggeo M, Bonora E, Corbellini M, Bressan F, De Marco R. Attending the Diabetes Center is associated with increased 5-year survival probability of diabetic patients. Diabetes Care. 1996;19:211-213.
47. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383-386.
48. Weinberger M, Kirkman MS, Samsa GP, et al. A nurse-coordinated intervention for primary care patients with NIDDM: Impact on glycemic control and health related quality of life. J Gen Intern Med. 1995;10:59-66.
49. Bero LA, Mays NB, Barjestech K, Bond C. Expanding the roles of outpatient pharmacists: Effects on health services utilisation, costs and patient outcomes. Cochrane Database of Systemic Reviews. 2000;3:CD00036.
50. Aubert RE, Herman WH, Waters J, et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organisation. Ann Intern Med. 1998;129:605-612.
51. Kinmonth AL, Woodcock A, Griffin, S, Spiegal N, Campbell J. Randomised controlled trial of patient centred care of diabetes in general practice: Impact on current wellbeing and future risk: The Diabetes Care From Diagnosis Research Team. BMJ. 1998;317:1202-1208.
52. Narayan KMV, Gregg EW, Engelgau MM, et al. Translation research for chronic diseases. The case for diabetes. Diabetes Care. 2000;23:1794-1798.